Everolimus is under clinical development by SoVarGen and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Everolimus’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Everolimus overview

Everolimus is under development for the treatment of intractable refractory epilepsy caused by focal cortical dysplasia. It is acts by targeting mTOR. It is administered through oral route.

SoVarGen overview

SoVarGen is a biotechnology company. The company’s product pipeline includes therapies for treatment of neurodevelopmental disorders, brain tumor, and neurodegenerative diseases. SoVarGen is headquartered in Daejeon, South Korea.

For a complete picture of Everolimus’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.